AdjuTec Pharma to start phase I trial with APC148

Adjutec is set to start its phase I clinical trial for the enzyme inhibitor APC148, marking a significant milestone for the company.
The trial begins September 18 with CTC in Uppsala and will focus on assessing the candidate’s safety.